NCT02335892

PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod

Patient Reported Outcomes With Fingolimod in Local Experience (PROFILE)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 114 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting multiple sclerosis patients. Patients will complete questionnaires at baseline, 3, 6 and 12 months.

Detailed description

Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting multiple sclerosis patients assessing the change in QoL and PRO outcome measures from baseline to 12 months after starting fingolimod. Patients will complete 4 questionnaires at baseline (prior to first fingolimod dose), then repeat them at 3, 6 and 12 month intervals via post.

Conditions

• Relapsing Remitting Multiple Sclerosis

Timeline

• Start date: 2014-11-11
• Primary completion: 2017-02-01
• Completion: 2017-02-01
• First posted: 2015-01-12
• Last updated: 2019-04-01

Locations

14 sites across 1 country: United Kingdom